April virtual meeting
29 April 2026

Liver Disease: Transforming Health Through Evidence

In April, Dr. Tegwinde Rebeca Compaoré led an engaging session on liver disease as a critical yet often overlooked public health issue across Africa — where hepatitis B and C carry a major burden and most people do not know their status.

Here is what she presented, what the room asked, and what should happen next.

1
Speakers
Hepatitis B & C
Focus
9
Key insights
42
Attendees

Meet the speaker.

Rebecca Compaore
Liver Disease
Dr. Tegwinde Rebeca Compaoré

Key insights from the session.

01 · LIVER HEALTH
The liver runs the whole system

It supports metabolism, detoxification, and immune function — protecting your liver protects the systems that keep you alive.

02 · GAPS
Innovation is not reaching everyone

Major gaps remain between research and real-world implementation, limiting the full impact of available solutions.

03 · EARLY DETECTION
Early detection changes outcomes

Screening lowers the risk of severe complications, reduces healthcare costs, improves quality of life, and is a better use of scarce healthcare resources.

04 · VACCINATION
Hepatitis B vaccination starts at day one

Vaccination is recommended to begin within 24 hours after birth, followed by scheduled doses in infancy.

05 · TRANSMISSION
Hepatitis C spreads through unsafe practices

Sharing blades and syringes, and certain African traditional procedures such as scarification, can transmit the virus.

06 · CURE
Hepatitis C can be cured in three months

Treatment can cure hepatitis C in as little as three months with proper adherence and follow-up.

07 · LOCAL CAPACITY
Most vaccines across Africa are imported

That underscores the need for locally developed vaccines tailored to regional virus strains.

08 · EVIDENCE
Research exists, but is underused

Evidence on hepatitis burden and screening is available — but is often underutilized in practice.

09 · THE FUTURE
The future is screening, local innovation, and AI

Stronger screening programs, scalable local innovations, precision medicine, and the integration of AI and big data will close the gap between what is known and what is done.

IN THE Q&A

Three questions from the room.

Question 01

Does liver disease increase the risk of cancer? Yes — chronic hepatitis B is a leading cause of liver cancer, which makes regular monitoring essential.

Question 02

Are screening and vaccination widely implemented? Newborn vaccination is common, but screening access remains limited in many areas — which drives late diagnosis.

Question 03

Is Africa moving toward local vaccine production? There is growing interest and advocacy, but progress requires investment, infrastructure, and partnerships.

TAKE ACTION TODAY

Three simple steps make the difference.

01

Get vaccinated

Hepatitis B vaccination is recommended within the first 24 hours after birth and continued on schedule through infancy.

02

Get tested regularly

Screening lowers the risk of severe complications and makes early treatment possible — hepatitis C can be cured in as little as three months.

03

Seek care early

If a test comes back positive, follow up promptly. Chronic hepatitis B is a leading cause of liver cancer, and monitoring keeps that risk in check.

DO YOU KNOW YOUR STATUS?
Do you know your hepatitis status?

Connaissez-vous votre statut vis-à-vis de l’hépatite ?

Taking this simple step could save your life — or the life of someone you care about.

GET THE RECAP

One issue a month. Nothing else.

Sent the week after each virtual meeting, with the recording and slides. Written for clinicians, researchers, and the people who fund and plan care.

Members get the recap plus the full session archive and CPD certificates. Join AHA →

Unsubscribe in one click. We never share your address.

PAST ISSUES
Previous issue
The state of cancer care in 2026 — equitable access across Africa
Read the recap →
Previous issue
How grant strategy meets RSV science — and why global health needs both
Read the recap →
Archive
Browse all past meeting recaps
See the archive →